Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 5Phase 3 4Phase 1 2

Status

Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × amivantamab × Clear all
NCT02609776 2026-06-05

CHRYSALIS

Janssen Research & Development, LLC

Phase 1 Active not recruiting
751 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-05-08

Chrysalis-2

Janssen Research & Development, LLC

Phase 1 Active not recruiting
701 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡